Archives
-
Tivozanib (AV-951): From Target to Phenotype
2026-09-07
Tivozanib and AV-951 offer a precise model for connecting VEGFR signaling pathway inhibition with measurable cancer-cell phenotypes. This article presents a mechanism-to-phenotype framework that separates cytostasis, cell killing, and anti-angiogenic effects for more interpretable oncology assays.
-
Cy3 Goat Anti-Mouse IgG (H+L) Antibody Workflow
2026-09-07
Build reproducible fluorescence, western blot, and flow cytometry workflows around a Cy3-labeled secondary antibody that amplifies mouse primary-antibody signals. The approach is especially useful for testing PMCA4b-dependent aldosterone signaling while preserving practical controls for specificity, storage, and spectral optimization.
-
Caspase-3 Colorimetric Assay Kit: Practical Guide
2026-09-05
The Caspase-3 Colorimetric Assay Kit (SKU K2008) provides a lysate-based method for measuring DEVD-dependent caspase-3 activity through release of p-nitroaniline at 405 or 400 nm. It is appropriate for prepared biological samples and apoptosis studies, but not for direct live-cell imaging or unprocessed complex tissues; this guide is based on the product dossier and workflow best practices rather than directly matched paper evidence.
-
Vidarabine Monohydrate: From Mechanism to Translation
2026-09-04
Vidarabine monohydrate is more than a catalog entry: it is a mechanistic probe for studying adenosine-mimetic disruption of viral DNA synthesis. This thought-leadership guide connects assay design, formulation discipline, translational evidence standards, and a carefully bounded lesson from recent SERT–nNOS research.
-
Cathepsin B inhibitor CA-074: Protocol Guide
2026-09-04
CA-074 (SKU A1926) provides selective cathepsin B inhibition for biochemical, cell-based, and disease-model workflows where separation from cathepsins H and L is important. This guide covers solvent selection, controls, storage, and interpretation boundaries; it is not appropriate as a broad-spectrum cysteine protease inhibitor or as evidence for outcomes beyond the supplied product dossier.
-
Caspase-3 Colorimetric Assay Kit in Macrophages
2026-09-03
Use the Caspase-3 Colorimetric Assay Kit to add a quantitative apoptosis layer to macrophage infection, ER-stress, and inflammatory-response studies. Its DEVD-pNA endpoint works with standard plate readers, providing a practical complement to ROS, pathway, and bacterial-clearance measurements.
-
Rotigotine Transdermal Delivery in PD and RLS
2026-09-03
The reference review explains how Rotigotine’s lipid solubility, receptor pharmacology, and rapid oral metabolism led to development of a transdermal system designed to provide continuous dopaminergic stimulation. It connects pharmacokinetic reasoning with clinical evidence for motor benefit in early- and advanced-stage Parkinson’s disease and symptom improvement in moderate-to-severe restless legs syndrome.
-
Imipenem: Linking PBPs to Resistance Assays
2026-09-02
Imipenem is a semisynthetic thienamycin antibiotic with a distinctive role in antibacterial research. This article connects its PBP mechanism with carbapenemase-gene localization, transfer assays, and immune-response experiments to improve interpretation of resistance studies.
-
DIDS: Reliable Cell Assay Design
2026-09-02
This scenario-based guide explains how DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid), SKU B7675, can be incorporated into cell viability, proliferation, cytotoxicity, and mechanistic ion-transport studies. It emphasizes solvent control, model-specific IC50 interpretation, orthogonal validation, and practical product-selection criteria.
-
SW033291: PGE2 Signaling for Regeneration
2026-09-01
SW033291 is a potent 15-PGDH inhibitor for studying prostaglandin E2 elevation, hematopoietic stem cell expansion, and tissue repair. This article translates new muscle-regeneration findings into practical assay decisions while clarifying what the compound can—and cannot—establish experimentally.
-
Glucose Uptake as a Lens on Sorafenib Resistance
2026-09-01
A translational framework for using fluorescence-based glucose uptake measurements to contextualize lipid reprogramming, ferroptosis, and sorafenib resistance in hepatocellular carcinoma without overstating what a single metabolic readout can prove.
-
SW033291: 15-PGDH Inhibitor Workflows
2026-08-31
SW033291 provides a practical way to test prostaglandin E2 elevation through selective 15-PGDH inhibition, with applications spanning enzyme assays, bone-marrow biology, and tissue regeneration research. This workflow-focused guide separates established hematopoietic evidence from emerging muscle-repair findings and highlights controls that improve interpretability.
-
BAPTA for Calcium Signaling & Apoptosis
2026-08-31
BAPTA provides a practical way to test whether calcium elevation is causal in toxicant-induced cell injury rather than merely associated with it. This workflow translates a nanoplastic–cadmium apoptosis study into reproducible calcium signaling modulation, assay controls, and troubleshooting strategies for cell-based research.
-
KG-501 for CREB Transcription Studies
2026-08-30
KG-501 provides a reversible way to test CREB–CBP KIX-domain signaling alongside macrophage-polarization and cancer assays. This guide connects compound handling, concentration design, orthogonal readouts, and troubleshooting to the TLR4-linked colitis-associated colorectal cancer model reported in the reference study.
-
Dihydroisotanshinone I Reverses Cisplatin Resistance
2026-08-29
This study identifies dihydroisotanshinone I as a potential sensitizer that restores Cisplatin responsiveness in resistant lung adenocarcinoma cells by promoting ferroptosis through PI3K-related signaling. Its combined viability, redox, iron, protein-expression, pathway, and docking analyses provide a useful framework for mechanistic chemotherapy resistance studies, while remaining limited to an in vitro model.